TISIDB

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type II membrane protein
Domain	PF01391 Collagen triple helix repeat (20 copies) PF00530 Scavenger receptor cysteine-rich domain
Function	Pattern recognition receptor (PRR) which binds Gram-positive and Gram-negative bacteria (PubMed:9468508). Also plays a role in binding of unopsonized particles by alveolar macrophages (By similarity). Binds to the secretoglobin SCGB3A2 (PubMed:12847263).

> Gene Ontology [ TOP ]
Biological Process	GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0006898 receptor-mediated endocytosis GO:0006909 phagocytosis GO:0031349 positive regulation of defense response GO:0043277 apoptotic cell clearance GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response
Molecular Function	GO:0005044 scavenger receptor activity GO:0008329 signaling pattern recognition receptor activity GO:0038024 cargo receptor activity GO:0038187 pattern recognition receptor activity
Cellular Component	GO:0005581 collagen trimer GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030666 endocytic vesicle membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome
Reactome	R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors R-HSA-3000480: Scavenging by Class A Receptors R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MARCO and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MARCO and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29667169	lung carcinoma	Promote immunity (infiltration)	On the transcriptomic level, we found a positive association between MARCO gene expression and general immune response pathways including strong links to immunosuppressive TAMs, T-cell infiltration and immune checkpoint molecules.

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MARCO in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MARCO in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.382	0.524
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.232	0.428
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.263	0.778
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.441	0.509
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.972	0.511
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.227	0.896
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.098	0.897
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.651	0.624
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.535	0.712
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.879	0.604
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.86	0.418
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.347	0.349

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MARCO in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	2.7	8.4	0.12
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	3.4	7.7	0.176
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	23.5	-4.5	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	16.7	8.3	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	27.3	-11.9	0.63
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	7.4	3.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MARCO. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MARCO. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MARCO. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MARCO. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MARCO expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MARCO and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MARCO
Name	macrophage receptor with collagenous structure
Aliases	SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location	2q14.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MARCO collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MARCO.

ID	Name	Drug Type	Targets	#Targets
DB09536	Titanium dioxide	Small Molecule	MARCO	1
DB11132	Silicon dioxide	Small Molecule	MARCO	1

Browse MARCO